{"id":"https://openalex.org/W2402069987","doi":null,"title":"Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib.","display_name":"Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib.","alternate_titles":[],"publication_year":2008,"publication_date":"2008-04-01","ids":{"openalex":"https://openalex.org/W2402069987","mag":"2402069987","pmid":"https://pubmed.ncbi.nlm.nih.gov/18496498"},"language":"en","primary_location":{"id":"pmid:18496498","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18496498","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical advances in hematology & oncology : H&O","raw_type":"Journal Article"},"parent_works":[],"lineage":["https://openalex.org/W2402069987"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5073761054","display_name":"Giovanni Martinelli","orcid":"https://orcid.org/0000-0002-1025-4210","observed_orcids":["https://orcid.org/0000-0002-1025-4210"]},"institutions":[{"id":"https://openalex.org/I9360294","display_name":"University of Bologna","ror":"https://ror.org/01111rn36","country_code":"IT","type":"education","lineage":["https://openalex.org/I9360294"]}],"countries":["IT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Giovanni Martinelli","raw_affiliation_strings":["Institute of Hematology and Medical Oncology, University of Bologna, 40138 Bologna, Italy. giovanni.martinelli2@unibo.it","Institute of Hematology and Medical Oncology, University of Bologna, 40138 Bologna, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institute of Hematology and Medical Oncology, University of Bologna, 40138 Bologna, Italy. giovanni.martinelli2@unibo.it","institution_ids":["https://openalex.org/I9360294"]},{"raw_affiliation_string":"Institute of Hematology and Medical Oncology, University of Bologna, 40138 Bologna, Italy","institution_ids":["https://openalex.org/I9360294"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Ilaria Iacobucci","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ilaria Iacobucci","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000893813","display_name":"Stefania Paolini","orcid":"https://orcid.org/0000-0002-5645-0364","observed_orcids":["https://orcid.org/0000-0002-5645-0364"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Stefania Paolini","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5023529754","display_name":"Emanuela Ottaviani","orcid":"https://orcid.org/0000-0002-1879-5417","observed_orcids":["https://orcid.org/0000-0002-1879-5417"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Emanuela Ottaviani","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.8305,"has_fulltext":false,"cited_by_count":19,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.85044596,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":96},"biblio":{"volume":"6","issue":"4","first_page":"303","last_page":"310"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.948199987411499,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.948199987411499,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":0.015399999916553497,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10169","display_name":"Protein Kinase Regulation and GTPase Signaling","score":0.007400000002235174,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tipifarnib","display_name":"tipifarnib","score":0.9919999837875366},{"id":"https://openalex.org/keywords/farnesyltransferase-inhibitors","display_name":"farnesyltransferase inhibitors","score":0.9599999785423279},{"id":"https://openalex.org/keywords/hematologic-malignancies","display_name":"hematologic malignancies","score":0.9980000257492065},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9070000052452087},{"id":"https://openalex.org/keywords/myelodysplastic-syndrome","display_name":"myelodysplastic syndrome","score":0.9819999933242798},{"id":"https://openalex.org/keywords/chronic-myeloid-leukemia","display_name":"chronic myeloid leukemia","score":0.9890000224113464},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":1.0},{"id":"https://openalex.org/keywords/ras-signaling","display_name":"Ras signaling","score":0.7379999756813049},{"id":"https://openalex.org/keywords/ras-mutations","display_name":"RAS mutations","score":0.6710000038146973},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6679999828338623},{"id":"https://openalex.org/keywords/imatinib","display_name":"imatinib","score":0.996999979019165},{"id":"https://openalex.org/keywords/etoposide","display_name":"etoposide","score":1.0}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8230401277542114},{"id":"https://openalex.org/C2778396349","wikidata":"https://www.wikidata.org/wiki/Q410994","display_name":"Farnesyltransferase","level":4,"score":0.5936488509178162},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.5834673643112183},{"id":"https://openalex.org/C2780817109","wikidata":"https://www.wikidata.org/wiki/Q954625","display_name":"Myelodysplastic syndromes","level":3,"score":0.5439685583114624},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5377794504165649},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.49496668577194214},{"id":"https://openalex.org/C2776960273","wikidata":"https://www.wikidata.org/wiki/Q729735","display_name":"Chronic myelogenous leukemia","level":3,"score":0.45892268419265747},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3653850555419922},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.22965332865715027},{"id":"https://openalex.org/C57790582","wikidata":"https://www.wikidata.org/wiki/Q901141","display_name":"Prenylation","level":3,"score":0.18756887316703796},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.1296248435974121},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.10985302925109863},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002454","descriptor_name":"Cell Differentiation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015398","descriptor_name":"Signal Transduction","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D019337","descriptor_name":"Hematologic Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D019337","descriptor_name":"Hematologic Neoplasms","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D049109","descriptor_name":"Cell Proliferation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D051231","descriptor_name":"Farnesyltranstransferase","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true}],"locations_count":2,"locations":[{"id":"pmid:18496498","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18496498","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical advances in hematology & oncology : H&O","raw_type":"Journal Article"},{"id":"pmh:oai:cris.unibo.it:11585/68464","doi":null,"is_oa":false,"landing_page_url":"http://hdl.handle.net/11585/68464","pdf_url":null,"source":{"id":"https://openalex.org/S4306402579","display_name":"Archivio istituzionale della ricerca (Alma Mater Studiorum Universit\u00e0 di Bologna)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210117483","host_organization_name":"Istituto di Ematologia di Bologna","host_organization_lineage":["https://openalex.org/I4210117483"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":41,"referenced_works":["https://openalex.org/W126176001","https://openalex.org/W194463696","https://openalex.org/W1653416607","https://openalex.org/W1921369660","https://openalex.org/W1955547739","https://openalex.org/W1969998496","https://openalex.org/W1973097976","https://openalex.org/W1979027806","https://openalex.org/W1996254906","https://openalex.org/W2008470915","https://openalex.org/W2021120405","https://openalex.org/W2024196844","https://openalex.org/W2025754007","https://openalex.org/W2036699032","https://openalex.org/W2044895975","https://openalex.org/W2059542017","https://openalex.org/W2077777928","https://openalex.org/W2080686981","https://openalex.org/W2081353268","https://openalex.org/W2102901045","https://openalex.org/W2102901804","https://openalex.org/W2122756958","https://openalex.org/W2131171876","https://openalex.org/W2143568970","https://openalex.org/W2149862494","https://openalex.org/W2151429860","https://openalex.org/W2155167738","https://openalex.org/W2156138425","https://openalex.org/W2167734044","https://openalex.org/W2172104048","https://openalex.org/W2225243160","https://openalex.org/W2255894651","https://openalex.org/W2315302561","https://openalex.org/W2551146143","https://openalex.org/W2555880945","https://openalex.org/W2566900228","https://openalex.org/W2567004787","https://openalex.org/W2568682809","https://openalex.org/W2569690486","https://openalex.org/W2591215796","https://openalex.org/W2991927770"],"related_works":["https://openalex.org/W1759110377","https://openalex.org/W2141585230","https://openalex.org/W2102287185","https://openalex.org/W34640787","https://openalex.org/W2133764101","https://openalex.org/W2089420365","https://openalex.org/W2056007788","https://openalex.org/W2161185323","https://openalex.org/W2115868832","https://openalex.org/W1988763143"],"abstract_inverted_index":{"Increased":[0],"understanding":[1],"of":[2,28,49,68,78,88,97,106,116,166,171],"the":[3,19,26,59,66,75,114,153],"cellular":[4,20],"mechanisms":[5,165],"associated":[6],"with":[7,100,129,163,177,189],"various":[8],"malignancies":[9,145],"has":[10],"allowed":[11],"researchers":[12],"to":[13,57],"develop":[14],"agents":[15,162,180],"that":[16,38,65,81,109,174],"selectively":[17],"target":[18,58],"proteins":[21],"and":[22,34,42,80,93,140,195,200],"pathways":[23,108],"implicated":[24,112],"in":[25,40,43,103,113,127,193,204],"pathogenesis":[27,115],"malignancy.":[29],"Tipifarnib":[30],"is":[31,71],"a":[32,47,104],"specific":[33],"potent":[35],"farnesyltransferase":[36],"inhibitor":[37],"demonstrates":[39],"vivo":[41],"vitro":[44],"activity":[45,102],"against":[46],"variety":[48,105],"human":[50],"cancers.":[51],"Although":[52],"tipifarnib":[53,82,176,188],"was":[54],"initially":[55],"thought":[56],"Ras":[60],"protein,":[61],"recent":[62],"evidence":[63],"suggests":[64],"presence":[67],"ras":[69],"mutations":[70],"not":[72],"necessary":[73],"for":[74,125],"antitumor":[76],"effects":[77,86],"tipifarnib,":[79,98],"may":[83],"exert":[84],"its":[85,101],"downstream":[87],"Ras.":[89],"The":[90],"oral":[91],"administration":[92],"favorable":[94],"toxicity":[95],"profile":[96],"combined":[99],"intracellular":[107],"have":[110,197],"been":[111,198],"hematologic":[117,144],"malignancies,":[118],"make":[119],"it":[120],"an":[121],"especially":[122],"attractive":[123],"agent":[124],"use":[126],"patients":[128],"acute":[130],"myeloid":[131],"leukemia":[132,138],"(AML),":[133],"myelodysplastic":[134],"syndromes,":[135],"chronic":[136],"myelogenous":[137],"(CML),":[139],"multiple":[141,150,161],"myeloma.":[142],"Because":[143],"are":[146,181],"likely":[147,159],"driven":[148],"by":[149],"genetic":[151],"aberrations,":[152],"most":[154],"effective":[155],"treatment":[156],"strategy":[157],"will":[158],"combine":[160],"complementary":[164],"action.":[167],"Thus,":[168],"additional":[169],"studies":[170,186],"combination":[172],"regimens":[173],"incorporate":[175],"other":[178],"antineoplastic":[179],"crucial.":[182],"Early":[183],"results":[184],"from":[185],"combining":[187],"imatinib":[190],"or":[191],"etoposide":[192],"CML":[194],"AML":[196],"promising":[199],"warrant":[201],"further":[202],"evaluation":[203],"larger":[205],"clinical":[206],"trials.":[207]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2402069987","counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
